b1banpc.jpg b1banph.jpg

GenSci

A pioneering genetic engineering pharmaceutical company with nearly 30 years of unwavering dedication to the healthcare industry

About GenSci

Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci), founded in 1997, is a subsidiary of Changchun High-Tech Industries (Group) Co., Ltd. (stock code: 000661.SZ). GenSci stands out as the only manufacturer to have three generations of recombinant human growth hormone (rhGH) worldwide, including Asia's first liquid formulation rhGH, Jintropin(®), and the world's first long-acting GH injection, Jintrolong(®). Over nearly three decades of development, GenSci has established deep expertise in pediatric and women's health, and emerges as a leader in biopharmaceuticals and innovative drug development including therapeutic areas of endocrinology & metabolism, immunology & respiratory diseases, and oncology. 


Innovation drives GenSci's growth. Our R&D efforts are centered on proprietary, advanced technology platforms, deep insights in key pathogenetic pathways, and sophisticated computational platforms, and supported by sustained high investment. Artificial intelligence(AI) is among the key technologies accelerating our development of transformative medicines for patients with high unmet medical needs.


Today, GenSci operates a fully integrated, end-to-end value chain for innovative medicines, from R&D, manufacturing, marketing, commercialization and service into a globally compliant framework. Also, GenSci has a strategic plan in key regions, including the USA, Europe, and Singapore, demonstrating our commitment to offering innovative healthcare solutions to patients globally. 

324324.jpg
  • 1997

    Establishment of Changchun GeneScience Pharmaceuticals Co., Ltd.

  • 9000+

    Employees

  • 13+

    Products Serving Countries and regions

  • 1,200+

    R&D personnel

  • 90+

    Patents

Our Values

  • b1img03.jpg
    Integrity

    We are steadfast in our commitment to ethical conduct and regulatory compliance, which forms the bedrock of our enduring legacy. Integrity is more than value; it is the essence of our corporate identity, steering every decision we make.

  • b1img05.jpg
    Innovation

    Innovation is our driving force. We are tireless in our pursuit of seeking opportunities and embracing differentiation, elevating modest ventures to benchmarks of excellence within our industry.

  • b1img04.jpg
    Excellence

    With a forward-looking perspective, we shape our present with strategic foresight. We meet every challenge with a pioneering spirit, enhancing our efficiency, and setting unassailable goals that propel us toward excellence.

  • b1img06.jpg
    Passion

    Central to our ethos is a deep-seated passion for the well-being of our patients and our team. We foster a culture that is rich in compassion and enthusiasm, ensuring that our professional excellence is matched by the genuine care we extend to every individual we engage with.

Milestones

2025

Partnership with ALK 

Exclusive rights to distribute 3 AIT products  in mainland China


Episil®

Exclusive commercial rights in China


2024

The First-in-Class in China

Jin Beixin®  Firsekibart, breakthrough therapy for acute gouty arthritis(NDA Acceptance)


The First Generics in china Jin Sai Xin* Aqueous SolutionProgesterone Injection()

 

The only drug with a clear oral dosage for cachexia in China

Megaxia® megestrol acetate oral suspension


Jintrolong®PEG-Somatropin

The world's first long-acting growth hormone injection approved for Turner Syndrome





2023

Shanghai Global Innovation Center Inaugurated

To accelerate the R&D process and bring more groundbreaking products and therapies to patients globally


2015

National Science and Technology Progress Second Class Prize

Awarded for excellence in original science and technology


2014

Jintrolong® PEG-rhGH

The world's first long-acting growth hormone injection, taking the lead globally for a decade


2008

Genfulin® Molgramostim Gel

Pioneered as a leading product in wound healing and tissue repair


2005

Jintropin® AQ rhGH Injection

The first liquid recombinant human growth hormone in Asia


1998

Jintropin® rhGH for Injection

The first recombinant human growth hormone produced in China


1997

Establishment of GenSci

Featuring genetic engineering, we began our journey to enhance the health of children with growth deficiencies in China